Semapimod
- CAS No.
- 352513-83-8
- Chemical Name:
- Semapimod
- Synonyms
- AXD-455;Cni-1493;Cni 1493;CPSI 2364;semapimod;N,N'-Bis[3,5-bis[1-[(aminoiminomethyl)hydrazono]ethyl]phenyl]decanediamide;Decanediamide, N1,N10-bis[3,5-bis[1-[2-(aminoiminomethyl)hydrazinylidene]ethyl]phenyl]-;N,N'-bis[3-[(E)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]-5-[(Z)-N-(diaminomethylideneamino)-C-methylcarbonimidoyl]phenyl]decanediamide
- CBNumber:
- CB91856072
- Molecular Formula:
- C34H52N18O2
- Molecular Weight:
- 744.9
- MDL Number:
- MFCD13195572
- MOL File:
- 352513-83-8.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| CNI-1493 95.00% | INB0000028 | 5MG | $497.05 |
| SEMAPIMOD 95.00% | API0005310 | 5MG | $497.27 |
| Density | 1.39 |
|---|---|
| pka | 14.28±0.70(Predicted) |
| FDA UNII | 9SGW2H1K8P |
Semapimod price
Semapimod Chemical Properties,Uses,Production
Uses
Semapimod, an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6. Semapimod inhibits TLR4 signaling (IC50≈0.3 μM). Semapimod inhibits p38 MAPK and nitric oxide production in macrophages. Semapimod has potential in a variety of inflammatory and autoimmune disorders[1][2][3].
in vivo
Semapimod (5 mg/kg; i.p; daily for 2 weeks) ameliorates endothelial dysfunction in Obese Zucker (OZ) rats[1].
Semapimod restores AM-induced akt phosphorylation and cGMP production in OZ rats[1].
Semapimod (6 mg/kg/day, Intracranially for 1 week) inhibits glioblastoma cell invasion in vivo[4].
Semapimod (intracranially administered, 2 weeks) semapimos strongly increases the survival of GL261 tumor-bearing animals in combination with radiation, but has no significant benefit in the absence of radiation[4].
| Animal Model: | Male OZ rats[1] |
| Dosage: | 5 mg/kg |
| Administration: | I.p; daily for 2 weeks |
| Result: | Restored endothelium-dependent vasorelaxation in OZ rats. |
| Animal Model: | C57Bl/6 mice (GL261 cells were orthotopically implanted)[4] |
| Dosage: | 6 mg/kg/day |
| Administration: | Intracranially for 1 week, delivered via an osmotic pump |
| Result: | Inhibited tumor cell invasion by more than 75%. |
IC 50
CD40; IL-1β; IL-6; p38 MAPK
References
[1] Nishimatsu H, et al. Blockade of endogenous proinflammatory cytokines ameliorates endothelial dysfunction in obese Zucker rats. Hypertens Res. 2008;31(4):737‐743. DOI:10.1291/hypres.31.737
[2] Wehner S, Set al. Inhibition of p38 mitogen-activated protein kinase pathway as prophylaxis of postoperative ileus in mice. Gastroenterology. 2009;136(2):619‐629. DOI:10.1053/j.gastro.2008.10.017
[3] Wang J, et al. Experimental Anti-Inflammatory Drug Semapimod Inhibits TLR Signaling by Targeting the TLR Chaperone gp96. J Immunol. 2016;196(12):5130‐5137. DOI:10.4049/jimmunol.1502135
[4] Miller IS, et al. Semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microglia. PLoS One. 2014 May 9;9(5):e95885. DOI:10.1371/journal.pone.0095885
Semapimod Preparation Products And Raw materials
Raw materials
Preparation Products
Semapimod Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19935 | 58 |
| Hangzhou MolCore BioPharmatech Co.,Ltd. | +86-057181025280; +8617767106207 | sales@molcore.com | China | 49709 | 58 |
| ShenZhen Trendseen Biological Technology Co.,Ltd. | 13417589054 | trendseenbio@gmail.com | China | 11674 | 58 |
| TargetMol Chemicals Inc. | 13564774135 | marketing@targetmol.com | United States | 19950 | 58 |
| JinOu Biomedical (Nanjing) Co., Ltd. | 13000000000 | jinoupharma@163.com | China | 11706 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Suzhou Meishi Biotechnology Co., Ltd. | 1173954148q | meishipharma@126.com | China | 20027 | 58 |
| ShenZhen Trendseen Biological Technology Co.,Ltd. | 13417589054 | trendseenbio@gmail.com | China | 9067 | 58 |
| Shanghai Easy CDMO Co.,Ltd | Info@easycdmo.com 13564957716 | Info@easycdmo.com | China | 9999 | 58 |
| Suzhou Haiben Pharmaceutical Co., Ltd | 19353112242 | 1816280386@qq.com | China | 8041 | 58 |
